23 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27994738	50	Sulfonamides as Selective Na	Amgen
26985315	49	Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.	Xenon Pharmaceuticals
25927480	36	Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.	Merck Research Laboratories
26101568	51	Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.	Pfizer
21300721	90	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.	University Of Oxford
25658507	218	Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.	Amgen
24601592	48	Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.	University College London
23121096	86	Ion channels as therapeutic targets: a drug discovery perspective.	Pfizer
17483457	58	A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.	Abbott Laboratories
18243692	85	Imidazopyridines: a novel class of hNav1.7 channel blockers.	Merck Research Laboratories
18176998	45	Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.	Abbott Laboratories
17804230	1	Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis.	Schering-Plough Research Institute
21106456	35	Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.	Merck Research Laboratories
20965738	78	Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.	Abbott Laboratories
20855211	91	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.	Abbott Laboratories
18501613	31	Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.	Abbott Laboratories
17489575	7	Sodium channel blockers.	Purdue Pharma
17228859	86	Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.	Pfizer